Sarcopenia and Mortality in Idiopathic Pulmonary Fibrosis
Author Information
Author(s): Fernández-Jiménez Rocío, Cabrera-Cesar Eva, Sanmartín-Sánchez Alicia, Sánchez-Garcia Ana, Espildora-Hernandez Francisco, Vegas-Aguilar Isabel, del Mar Amaya-Campos Maria, Guirado-Pelaez Patricia, Simón-Frapolli Victor, Murri Mora, Garrido-Sánchez Lourdes, Piñel-Jimenez Lorena, Cano-Gamonoso Miguel Benítez, López-García Javier, Gómez-Rodríguez Belén, Velasco-Garrido Jose Luis, Tinahones Francisco J., García-Almeida José Manuel
Primary Institution: Virgen de la Victoria University Hospital, Malaga, Spain
Hypothesis
The study investigates the prevalence and clinical implications of sarcopenia in patients with idiopathic pulmonary fibrosis (IPF) using morphofunctional assessment methods.
Conclusion
Sarcopenia is prevalent in IPF patients and is associated with greater disease severity and reduced quality of life.
Supporting Evidence
- Sarcopenia was prevalent in 20.2% of the cohort.
- Sarcopenic patients exhibited significantly lower forced vital capacity (FVC) compared to non-sarcopenic patients.
- Sarcopenic patients had worse quality of life as measured by SGRQ impact scores.
- RFCSA and TUG are good predictors of sarcopenia and 12-month mortality.
- Patients with RFCSA sarcopenia had a 2.37 times higher risk of mortality.
- TUG sarcopenia presented a 4.89 times higher risk of adverse events.
- Identified cutoff values for RFCSA, TUG, and BCM were established for predicting sarcopenia.
Takeaway
Sarcopenia is when people lose muscle mass and strength, and it can make patients with lung disease feel worse and live shorter lives.
Methodology
The study used bioelectrical impedance analysis, handgrip strength, Timed Up and Go test, and nutritional ultrasound to assess sarcopenia in IPF patients.
Limitations
The study had a predominantly male sample and a cross-sectional design, which may limit the generalizability of the results.
Participant Demographics
Predominantly male, mean age of 71 years.
Statistical Information
P-Value
p=0.045 for RFCSA, p=0.011 for TUG
Confidence Interval
95% CI: 1.02–5.48 for RFCSA, 95% CI: 1.43–16.70 for TUG
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website